Intensity Therapeutics, Inc.(INTS)Earnings, Financials & Key Ratios
INTS•NASDAQ
$5.11
$13M mkt cap·Price updated May 7, 2026
AboutIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Show more
- Revenue$0
- EBITDA-$16M-99.1%
- Net Income-$16M-54.4%
- EPS (Diluted)-29.25+15.2%
- ROE-202.34%-152.7%
- ROIC-475.67%
- Debt/Equity0.05+294.0%
INTS Key Insights
Intensity Therapeutics, Inc. (INTS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 11 (bottom 11%)
- ✗Shares diluted 61.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
INTS Price & Volume
Intensity Therapeutics, Inc. (INTS) stock price & volume — 10-year historical chart
Loading chart...
INTS Growth Metrics
Intensity Therapeutics, Inc. (INTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM27.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM46.44%
Return on Capital
10 Years-141.21%
5 Years-158.5%
3 Years-201.89%
Last Year-202.7%
INTS Recent Earnings
Intensity Therapeutics, Inc. (INTS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (33%)
Q4 2025Latest
Nov 6, 2025EPS
$0.06
Est $0.06
+0.0%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.13
Est $0.06
-116.7%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.22
Est $0.21
-4.8%
Revenue
—
Q2 2025
Mar 13, 2025EPS
$0.22
Est $0.23
+4.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 6, 2025 | $0.06vs $0.06+0.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.13vs $0.06-116.7% | — |
| Q2 2025 | May 13, 2025 | $0.22vs $0.21-4.8% | — |
| Q2 2025 | Mar 13, 2025 | $0.22vs $0.23+4.3% | — |
Based on last 12 quarters of dataView full earnings history →
INTS Peer Comparison
Intensity Therapeutics, Inc. (INTS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 CLDX | 2.22B | 33.32 | -8.54 | -78.63% | -172.53% | -41.68% | 0.00 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 ADCT | 478.24M | 3.76 | -3.36 | 14.85% | -173.02% | |||
 IMCR | 1.55B | 30.62 | -57.77 | 20% | -4.88% | -4.83% | 0.11 | |
 IOVA | 1.27B | 3.55 | -3.26 | 60.6% | -123.9% | -50.17% | 0.07 | |
 IMMP | 63.65M | 0.43 | -1.42 | 31.28% | -11.72% | -72.51% | 0.01 | |
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% |
Compare INTS vs Peers
Intensity Therapeutics, Inc. (INTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INTS Income Statement
Intensity Therapeutics, Inc. (INTS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 147K | 0 | 6K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -147K▲ 0% | 0▲ 100.0% | -6K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | 100% | - |
| Operating Expenses | 5.68M | 6.22M | 8.01M | 7.55M | 8.17M | 16.59M | 12.04M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.24M | 1.17M | 2.14M | 2.42M | 3.39M | 6.09M | 4.79M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 4.44M | 5.05M | 5.86M | 5.13M | 4.79M | 10.5M | 7.25M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 17.22K | 0 | 0 | 0 | 0 |
| Operating Income | -5.68M▲ 0% | -6.22M▼ 9.7% | -8.01M▼ 28.8% | -7.55M▲ 5.8% | -8.32M▼ 10.2% | -16.59M▼ 99.4% | -12.04M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -9.65% | -28.77% | 5.79% | -10.19% | -99.36% | - |
| EBITDA | -5.5M | -6.03M | -7.88M | -7.5M | -8.17M | -16.27M | -9.28M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -9.57% | -30.64% | 4.8% | -8.96% | -99.07% | 43.72% |
| D&A (Non-Cash Add-back) | 171.86K | 0 | 0 | 0 | 147K | 0 | 2.73M |
| EBIT | -5.38M | -6.03M | -7.88M | -7.5M | -10.23M | -16.27M | -11.95M |
| Net Interest Income | 150.71K | 74.01K | -14.16K | -79.3K | 19K | 314K | 119K |
| Interest Income | 150.71K | 74.01K | 2.61K | 2.48K | 324K | 314K | 119K |
| Interest Expense | 0 | 0 | 16.77K | 81.78K | 305K | 0 | 0 |
| Other Income/Expense | 295.7K | 192.77K | 118.58K | -32K | -2.22M | 317K | 299K |
| Pretax Income | -5.38M▲ 0% | -6.03M▼ 12.1% | -7.9M▼ 30.9% | -7.58M▲ 4.0% | -10.54M▼ 39.0% | -16.27M▼ 54.4% | -11.74M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.23M▲ 0% | -5.96M▼ 13.9% | -7.9M▼ 32.6% | -7.58M▲ 4.0% | -10.54M▼ 39.0% | -16.27M▼ 54.4% | -11.74M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -13.91% | -32.55% | 3.97% | -38.99% | -54.37% | 27.82% |
| Net Income (Continuing) | -5.38M | -6.03M | -7.9M | -7.58M | -10.54M | -16.27M | -11.74M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -39.50▲ 0% | -44.25▼ 12.0% | -58.00▼ 31.1% | -55.50▲ 4.3% | -34.50▲ 37.8% | -29.25▲ 15.2% | -6.82▲ 0% |
| EPS Growth % | - | -12.03% | -31.07% | 4.31% | 37.84% | 15.22% | 46.44% |
| EPS (Basic) | -39.50 | -44.25 | -58.00 | -55.50 | -34.50 | -29.25 | - |
| Diluted Shares Outstanding | 136.12K | 136.38K | 136.4K | 136.4K | 344.65K | 556.28K | 1.72M |
| Basic Shares Outstanding | 136.08K | 136.36K | 136.4K | 136.4K | 306.16K | 556.24K | 1.72M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
INTS Balance Sheet
Intensity Therapeutics, Inc. (INTS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.65M | 9.48M | 4.73M | 1.45M | 15.46M | 3.36M | 8.19M |
| Cash & Short-Term Investments | 8.39M | 9.32M | 4.54M | 1.31M | 14.78M | 2.59M | 7.07M |
| Cash Only | 3.83M | 9.32M | 4.54M | 1.31M | 8.56M | 2.59M | 7.07M |
| Short-Term Investments | 4.56M | 0 | 0 | 0 | 6.22M | 0 | 0 |
| Accounts Receivable | 33.63K | 48.52K | 51.26K | 62.3K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 166.47K | 46.17K | 69.28K | 13.7K | 6K | 0 | 1.12M |
| Total Non-Current Assets | 357.11K | 671.94K | 485.86K | 306K | 1.83M | 1.42M | 1.4M |
| Property, Plant & Equipment | 252.67K | 490.24K | 318.13K | 139K | 147K | 122K | 103K |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 75K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 29.44K | 181.7K | 167.74K | 167K | 1.68M | 1.3M | 5.19M |
| Total Assets | 9.01M▲ 0% | 10.15M▲ 12.7% | 5.22M▼ 48.6% | 1.76M▼ 66.3% | 17.3M▲ 884.3% | 4.78M▼ 72.3% | 9.59M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 12.7% | -48.61% | -66.32% | 884.35% | -72.34% | -112.55% |
| Total Current Liabilities | 1.13M | 1.35M | 3.72M | 6.82M | 3.96M | 1.75M | 2.28M |
| Accounts Payable | 393.96K | 222.71K | 172.51K | 603K | 3.05M | 1.22M | 1.68M |
| Days Payables Outstanding | - | - | - | - | 7.57K | - | 86.41K |
| Short-Term Debt | 117.19K | 0 | 2.02M | 4.35M | 0 | 0 | 31K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.52K | 0 | 0 | 0 | 499K | 56K | 561K |
| Current Ratio | 7.67x | 7.04x | 1.27x | 0.21x | 3.91x | 1.92x | 1.92x |
| Quick Ratio | 7.67x | 7.04x | 1.27x | 0.21x | 3.91x | 1.92x | 1.92x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 179.08K | 10.36M | 10.18M | 10.04M | 174K | 110K | 87K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 87K |
| Capital Lease Obligations | 143.08K | 326.25K | 143.57K | 0 | 138K | 110K | 307K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 36K | 10.04M | 10.04M | 10.04M | 36K | 0 | 0 |
| Total Liabilities | 1.31M | 11.71M | 13.9M | 16.86M | 4.13M | 1.86M | 2.36M |
| Total Debt | 260.27K | 497.48K | 2.34M | 4.49M | 158K | 138K | 118K |
| Net Debt | -3.57M | -8.82M | -2.2M | 3.18M | -8.4M | -2.45M | -6.95M |
| Debt / Equity | 0.03x | - | - | - | 0.01x | 0.05x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.75x |
| Interest Coverage | - | - | -477.95x | -92.32x | -27.28x | - | - |
| Total Equity | 7.7M▲ 0% | -1.56M▼ 120.2% | -8.68M▼ 457.3% | -15.1M▼ 73.9% | 13.16M▲ 187.2% | 2.92M▼ 77.8% | 7.22M▲ 0% |
| Equity Growth % | - | -120.24% | -457.27% | -73.86% | 187.18% | -77.83% | -73.66% |
| Book Value per Share | 56.56 | -11.43 | -63.66 | -110.69 | 38.19 | 5.25 | 4.19 |
| Total Shareholders' Equity | 7.7M | -1.56M | -8.68M | -15.1M | 13.16M | 2.92M | 7.22M |
| Common Stock | 681 | 682 | 341 | 0 | 1K | 2K | 5K |
| Retained Earnings | 0 | -23.18M | -31.07M | -38.65M | -50.52M | -66.78M | -75.34M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -17.15M | 0 | 0 | 0 | -17.3M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INTS Cash Flow Statement
Intensity Therapeutics, Inc. (INTS) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.42M | -5.37M | -6.83M | -5.48M | -7.21M | -15.22M | -15.22M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -21.6% | -27.13% | 19.77% | -31.54% | -111.24% | -45.62% |
| Net Income | -5.38M | -6.03M | -7.9M | -7.58M | -10.54M | -16.27M | -11.74M |
| Depreciation & Amortization | 0 | 0 | 0 | 179.04K | 0 | 0 | 12K |
| Stock-Based Compensation | 561.38K | 555.49K | 719.82K | 1.17M | 1.4M | 3.07M | 1.92M |
| Deferred Taxes | 0 | 0 | 0 | -179.04K | 0 | 0 | 0 |
| Other Non-Cash Items | 95.21K | 116.83K | 172.11K | 178.86K | 2.57M | 76K | 376K |
| Working Capital Changes | 306.91K | -12.03K | 176.8K | 756.69K | -633K | -2.1M | -75K |
| Change in Receivables | 0 | 0 | 16.77K | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 202.55K | -171.26K | -50.2K | 430.67K | 1.63M | -2.27M | -70K |
| Cash from Investing | 1.7M | 4.56M | 0 | 0 | -6.02M | 6.35M | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 3.86M | 6.29M | 2.05M | 2.25M | 20.47M | 2.9M | 13.79M |
| Debt Issued (Net) | 0 | 0 | 2M | 2.25M | 230K | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 0 | 0 | 1000K | 1000K | 3.33M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 25K | 50K | 0 | -2.18M | -332K | -524K |
| Net Change in Cash | 1.14M▲ 0% | 5.49M▲ 381.7% | -4.78M▼ 187.1% | -3.23M▲ 32.4% | 7.24M▲ 324.5% | -5.97M▼ 182.4% | 4.29M▲ 0% |
| Free Cash Flow | -4.42M▲ 0% | -5.37M▼ 21.6% | -6.83M▼ 27.1% | -5.48M▲ 19.8% | -7.21M▼ 31.5% | -15.22M▼ 111.2% | -9.5M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -21.6% | -27.13% | 19.77% | -31.54% | -111.24% | 29.63% |
| FCF per Share | -32.44 | -39.38 | -50.05 | -40.16 | -20.91 | -27.36 | -27.36 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.90x | 0.86x | 0.72x | 0.68x | 0.94x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INTS Key Ratios
Intensity Therapeutics, Inc. (INTS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -194% | - | - | -80.06% | -202.34% | -370.86% |
| Return on Invested Capital (ROIC) | - | - | - | - | -475.67% | -475.67% |
| Debt / Equity | - | - | - | 0.01x | 0.05x | 0.05x |
| Interest Coverage | - | -477.95x | -92.32x | -27.28x | - | - |
| FCF Conversion | 0.90x | 0.86x | 0.72x | 0.68x | 0.94x | 0.81x |
INTS Frequently Asked Questions
Intensity Therapeutics, Inc. (INTS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Intensity Therapeutics, Inc. (INTS) grew revenue by 0.0% over the past year. Growth has been modest.
Intensity Therapeutics, Inc. (INTS) reported a net loss of $11.7M for fiscal year 2024.
Dividend & Returns
Intensity Therapeutics, Inc. (INTS) has a return on equity (ROE) of -202.3%. Negative ROE indicates the company is unprofitable.
Intensity Therapeutics, Inc. (INTS) had negative free cash flow of $9.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More INTS
Intensity Therapeutics, Inc. (INTS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates